Drugs / Pirfenidoneone
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06912763 | Aug 2025 → Mar 2031 expected | head and neck cancer, lymphedema | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pirfenidoneone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06912763 ↗ |
| Route | Oral | “Given PO” NCT06912763 ↗ |